ISPOR - OP8 A New Complement Inhibitor: Impact of Ravulizumab on Eculizumab and Future Biosimilars Use, and Role of Paris Public Hospitals (AP-HP)

OP8 A New Complement Inhibitor: Impact of Ravulizumab on Eculizumab and Future Biosimilars Use, and Role of Paris Public Hospitals (AP-HP)

Abstract

Authors

C. Romero I. Fusier V. Siorat P. Mougenot P. Paubel

Full Text Cite This Article

Back to Volume 26, Supplemental Issue 12S

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now